Table 4.
Patient outcome for 52 patients with follow-up available
| All patients | A, NED | A, D | D, NED | D, D | |
|---|---|---|---|---|---|
| All patients with follow-up (months) | 52 (36.1) | 18 (69.6) | 7 (11.0) | 1 (63.7) | 26 (18.5) |
| Follow-up range (months) | 2.4–286 | 2.5–286 | 2.5–24.0 | 63.7 | 2.4–75.2 |
| Sex | |||||
| Males (mean, years) | 26 (25.5) | 6 (47.8) | 5 (11.2) | n/a | 15 (22.5) |
| Females (mean, years) (p = 0.202) | 26 (46.0) | 12 (80.5) | 2 (10.6) | 1 (63.7) | 11 (13.1) |
| Size a | |||||
| ≤5.0 cm | 14 (57.5) | 6 (109.8) | n/a | n/a | 8 (19.0) |
| >5.0 cm (p = 0.064) | 25 (25.7) | 6 (60.6) | 6 (12.3) | 1 (63.7) | 13 (11.6) |
| Anatomic site | |||||
| Single site | 6 (77.3) | 2 (188.3) | 1 (24) | n/a | 3 (21.2) |
| Mixed site (p = 0.02) | 46 (30.7) | 16 (54.8) | 6 (8.8) | 1 (63.7) | 23 (18.2) |
| Immunohistochemistry a | |||||
| Keratin/CAM5.2/CK5/6 positive | 27 (39.8) | 10 (74.8) | 5 (11.2) | 1 (63.7) | 11 (18.7) |
| No epithelial reactivity (p = 0.669) | 23 (33.6) | 8 (63.1) | 2 (10.6) | n/a | 13 (19.0) |
| Stage (IRSG grouping) | |||||
| II | 2 (55.5) | 2 (55.2) | n/a | n/a | n/a |
| III | 26 (57.4) | 13 (76.5) | 3 (11.5) | 1 (63.7) | 9 (18.8) |
| IV (p = 0.068) | 24 (20.9) | 3 (49.4) | 4 (10.7) | n/a | 17 (18.3) |
A, NED alive, no evidence of disease; A, D alive with disease; D, NED dead, no evidence of disease; D, D dead with disease; n/a not applicable
aSize was not reported in all cases